Retinal Vein Occlusion - Pipeline Review, H1 2018

  • ID: 4542975
  • Report
  • 106 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acucela Inc
  • Celon Pharma SA
  • Eyevensys SAS
  • Graybug Vision Inc
  • Mabion SA
  • Ocular Therapeutix Inc
  • MORE
Retinal Vein Occlusion - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2018, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights:

This latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 3, 11, 1 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acucela Inc
  • Celon Pharma SA
  • Eyevensys SAS
  • Graybug Vision Inc
  • Mabion SA
  • Ocular Therapeutix Inc
  • MORE
Introduction

Report Coverage

Retinal Vein Occlusion - Overview

Retinal Vein Occlusion - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Retinal Vein Occlusion - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinal Vein Occlusion - Companies Involved in Therapeutics Development

Acucela Inc

Addmedica SAS

Annexin Pharmaceuticals AB

Celon Pharma SA

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Clearside BioMedical Inc

EyeGate Pharmaceuticals Inc

Eyevensys SAS

Formycon AG

Gene Signal International SA

Graybug Vision Inc

Lupin Ltd

Mabion SA

Novartis AG

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Profarma

Regeneron Pharmaceuticals Inc

SciFluor Life Sciences LLC

ThromboGenics NV

Retinal Vein Occlusion - Drug Profiles

ACU-6151 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aganirsen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKB-9778 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

conbercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EYS-609 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxyurea - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LKA-651 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ocriplasmin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTX-TKI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Inhibit VEGF for Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0166 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

squalamine lactate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triamcinolone acetonide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinal Vein Occlusion - Dormant Projects

Retinal Vein Occlusion - Discontinued Products

Retinal Vein Occlusion - Product Development Milestones

Featured News & Press Releases

May 09, 2018: Clearside Biomedical Provides Update on Pivotal Phase 3 Trial Results of Suprachoroidal CLS-TA

Mar 06, 2018: Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

Jun 08, 2017: Clearside Biomedical’s TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting

Feb 16, 2017: Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion

Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting

Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion

Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion

Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration

Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion

Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion

Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion

Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion

Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Retinal Vein Occlusion - Pipeline by Acucela Inc, H1 2018

Retinal Vein Occlusion - Pipeline by Addmedica SAS, H1 2018

Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H1 2018

Retinal Vein Occlusion - Pipeline by Celon Pharma SA, H1 2018

Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2018

Retinal Vein Occlusion - Pipeline by Clearside BioMedical Inc, H1 2018

Retinal Vein Occlusion - Pipeline by EyeGate Pharmaceuticals Inc, H1 2018

Retinal Vein Occlusion - Pipeline by Eyevensys SAS, H1 2018

Retinal Vein Occlusion - Pipeline by Formycon AG, H1 2018

Retinal Vein Occlusion - Pipeline by Gene Signal International SA, H1 2018

Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H1 2018

Retinal Vein Occlusion - Pipeline by Lupin Ltd, H1 2018

Retinal Vein Occlusion - Pipeline by Mabion SA, H1 2018

Retinal Vein Occlusion - Pipeline by Novartis AG, H1 2018

Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H1 2018

Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc, H1 2018

Retinal Vein Occlusion - Pipeline by Profarma, H1 2018

Retinal Vein Occlusion - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Retinal Vein Occlusion - Pipeline by SciFluor Life Sciences LLC, H1 2018

Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H1 2018

Retinal Vein Occlusion - Dormant Projects, H1 2018

Retinal Vein Occlusion - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Retinal Vein Occlusion, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acucela Inc
  • Addmedica SAS
  • Annexin Pharmaceuticals AB
  • Celon Pharma SA
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Clearside BioMedical Inc
  • EyeGate Pharmaceuticals Inc
  • Eyevensys SAS
  • Formycon AG
  • Gene Signal International SA
  • Graybug Vision Inc
  • Lupin Ltd
  • Mabion SA
  • Novartis AG
  • Ocular Therapeutix Inc
  • Ohr Pharmaceutical Inc
  • Profarma
  • Regeneron Pharmaceuticals Inc
  • SciFluor Life Sciences LLC
  • ThromboGenics NV
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll